Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
U.S. listed: $CRDLBiotech · Cardiovascular medicineExecution and funding risks
CRDL Stock Hub: Cardiol Therapeutics News, CardiolRx and MAVERIC
Cardiol has a late-stage oral candidate for recurrent pericarditis, supported by an encouraging uncontrolled pilot and a pivotal randomized trial. MAVERIC reached its original 110-patient target; expansion to up to 150 is planned after fewer pooled recurrences than expected. The blinded observation cannot establish efficacy. Additional enrollment and event collection move the decisive readout to mid-2027. Funding guidance extends beyond that window under management’s assumptions, while trial failure, additional evidence requirements and future financing remain material risks. ARCHER did not meet its two primary imaging endpoints in myocarditis, so its exploratory findings do not validate the pericarditis program.
Full research report · PDF
Cardiol Therapeutics ($CRDL), archive captured October 31, 2026
17 pages covering The report examines CardiolRx in recurrent pericarditis, the uncontrolled pilot evidence, the expanded pivotal MAVERIC trial and the separate ARCHER myocarditis program. It distinguishes blinded event observations from efficacy, and follows Canadian-dollar financial statements, subsequent U.S.-dollar financing and the assumptions behind runway guidance. The original research revision date is not stated; the date above records when this archive copy was captured. The hub follows later developments. For personal use only: redistribution prohibited.
Next company milestone
Mid-2027
Expanded MAVERIC trial: topline results are expected in mid-2027. Primary source
Company-guided windows remain forecasts; completed events are dated separately from the next operating or financial disclosure.
CRDL stock at a glance
Close · October 30, 2026
$1.11
Regular-session close; -5.13% versus $1.17 on October 29. USD.
Cash · June 30, 2026
C$26.081M
Canadian-dollar company accounts; separate from the USD share price.
Operating cash use · H1 2026
C$11.897M
Six months ended June 30, 2026.
Current liabilities · June 30, 2026
C$5.262M
Includes a C$1.474M non-cash derivative liability.
MAVERIC original enrollment
110 patients
Target met, announced September 23, 2026.
MAVERIC planned expansion
Up to 150
Blinded aggregate event review does not establish efficacy.
MAVERIC topline window
Mid-2027
Company guidance, without a fixed release day.
Runway forecast
Into Q1 2028
Company forecast dated September 23, 2026; not current cash.
Where Cardiol Therapeutics stands now
Cardiol has a late-stage oral candidate for recurrent pericarditis, supported by an encouraging uncontrolled pilot and a pivotal randomized trial. MAVERIC reached its original 110-patient target; expansion to up to 150 is planned after fewer pooled recurrences than expected. The blinded observation cannot establish efficacy. Additional enrollment and event collection move the decisive readout to mid-2027. Funding guidance extends beyond that window under management’s assumptions, while trial failure, additional evidence requirements and future financing remain material risks. ARCHER did not meet its two primary imaging endpoints in myocarditis, so its exploratory findings do not validate the pericarditis program.
Execution and funding. There is no operating revenue and the company remains dependent on capital. MAVERIC reached its original 110-patient target, but expansion to up to 150 and the mid-2027 readout extend execution risk. The blinded aggregate event review cannot establish efficacy; the earlier Phase II study was open-label in 27 patients. The 27-site count and four Italian sites previously listed as not yet recruiting refer to the September 2 registry snapshot.
The constructive case
The June quarter reported C$26.08 million of cash and a C$6.08 million net loss. Following September warrant proceeds, management’s September 23 forecast is runway into Q1 2028, including MAVERIC completion. The original 110-patient enrollment target was reached and expansion to up to 150 was planned; the next efficacy test remains the mid-2027 readout. Published Phase II pericarditis observations and FDA orphan designation support development, but neither establishes randomized benefit or approval.
The cautious case
There is no operating revenue and the company remains dependent on capital. MAVERIC reached its original 110-patient target, but expansion to up to 150 and the mid-2027 readout extend execution risk. The blinded aggregate event review cannot establish efficacy; the earlier Phase II study was open-label in 27 patients. The 27-site count and four Italian sites previously listed as not yet recruiting refer to the September 2 registry snapshot.
Latest Cardiol Therapeutics news
Sep 23, 2026
MAVERIC reaches its original enrollment target; expansion planned
On September 23, 2026, Cardiol confirmed that MAVERIC had enrolled 110 patients, meeting its original target ahead of schedule. The steering committee recommends expansion to up to 150 patients after a blinded review found fewer recurrences than expected. Topline results are now expected in mid-2027.
Sep 20, 2026
$150M Preliminary Shelf and Expanded Program Disclosure
The US$150 million base shelf was finalized September 15, 2026; the amended Form F-10 became effective September 16 under Rule 467(a). Effectiveness creates registration capacity, not cash. The September 16 supplement registers resale of 15,037,500 shares: 10,025,000 already issued and 5,012,500 issuable on warrant exercise. Resale proceeds belong to selling shareholders, not Cardiol; warrant exercise proceeds are a separate transaction. September 16 supplement; F-10 amendment.
Sep 9, 2026
H.C. Wainwright fireside chat on September 14
Cardiol announced a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 10:30 a.m. EDT. The announced date has passed; the event was an investor presentation, not a scheduled data release. This is an investor event, not an announced clinical readout or confirmation that MAVERIC enrollment is complete.
Aug 12, 2026
The loss narrowed to C$6.08M, the smallest quarter in two years
Net loss for the quarter ended June 30 was C$6,081,827, C$0.05 per share, against C$8,354,371 a year earlier and C$10,818,589 in the first quarter of 2026. The quarter carried C$4,741,864 of general and administrative expense and C$3,196,057 of research and development. Cardiol has no operating revenue, so the line that moves is spending, not sales.
Aug 12, 2026
CRD-38 development spending and IND-enabling work
The Q2 discussion places CRD-38 in formulation optimization and IND-enabling studies, with completion anticipated in H1 2027. It is not an active human study or a confirmed first-patient date.
Aug 12, 2026
ARCHER next steps remain under evaluation
The reported myocarditis program remains distinct from pivotal MAVERIC. ARCHER missed both co-primary endpoints; supportive structural signals do not establish a new registration study or approval schedule.
CRDL stock catalysts and company milestones
- Mid-2027 — Expanded MAVERIC trial: topline results are expected in mid-2027. Company guidance; no exact results day
Company profile and pipeline
Cardiol Therapeutics is a Canadian clinical-stage life-sciences company founded in 2017 and headquartered in Ontario. Its common shares trade on Nasdaq and the Toronto Stock Exchange under CRDL. The strategy centers on pharmaceutically manufactured cannabidiol formulations intended to modulate inflammatory and fibrotic pathways in heart disease.
Cardiol is not a consumer-cannabis company. CardiolRx is a chemically synthesized, high-concentration oral drug product manufactured under pharmaceutical standards. The relevant question is whether the specific formulation and dose produce reproducible efficacy and acceptable safety in a defined cardiovascular population.
Cash, burn rate and dilution: funded through the readout, not dilution-free
Cardiol ended June 2026 with C$26.08 million of cash and equivalents, C$29.23 million of current assets and C$5.26 million of current liabilities, including a C$1.47 million derivative liability. Working capital was C$23.96 million, or C$25.44 million excluding that non-cash derivative liability. Management’s September 23 update forecasts runway into Q1 2028 after subsequent warrant proceeds; this remains a forecast, not a restated June balance.
Cash fell by only C$1.59 million from March 31 to June 30 because operating use was partly offset by roughly C$2.48 million of Q2 net financing cash and foreign-exchange effects. A single quarter does not establish a stable burn rate or independently validate management’s current Q1 2028 runway forecast. Contractual obligations totaled C$5.95 million, with C$5.25 million due within one year; there were no disclosed capital-expenditure commitments.
Merlintrader Health Score · $CRDL
3.10out of 5
Assessed October 4, 2026. Weighted calculation: 3.5×30% + 3.0×30% + 2.5×20% + 3.0×10% + 3.5×10% = 3.10. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- There is no operating revenue and the company remains dependent on capital. MAVERIC reached its original 110-patient target, but expansion to up to 150 and the mid-2027 readout extend execution risk. The blinded aggregate event review cannot establish efficacy; the earlier Phase II study was open-label in 27 patients. The 27-site count and four Italian sites previously listed as not yet recruiting refer to the September 2 registry snapshot.
- Company forecasts depend on execution and may change.
- Financial balances retain their stated reporting date; later financing is separate.
- Investment involves possible loss of part or all of the capital.
CRDL Stock FAQ: Cardiol Therapeutics Questions Answered
How many patients are in the MAVERIC Phase III trial?
Cardiol confirmed on September 23, 2026 that MAVERIC had enrolled 110 patients, meeting its original target ahead of schedule. The steering committee has recommended expanding to up to 150 patients after a blinded review found fewer recurrences than the design assumed. Enrollment of 150 has not been reported as complete.
When are MAVERIC topline results expected?
Mid-2027. That replaces the previous guidance of the first quarter of 2027, and the change follows the recommended expansion of the trial, which is intended to capture enough events to preserve the planned statistical power.
Does the blinded review showing fewer recurrences mean CardiolRx is working?
No. The review is blinded and pools the treatment groups, so it cannot show whether CardiolRx outperforms placebo. A lower overall event rate is consistent with a treatment effect and equally consistent with a placebo group doing better than the design assumed. Only the randomised readout separates them.
How long is Cardiol funded for?
Management states that existing capital funds MAVERIC to completion and puts the cash runway into the first quarter of 2028. The September 16, 2026 release had said the first half of 2028, after warrant exercises of over US$7 million. Neither statement is a newly reported cash balance, and neither guarantees financing through commercialisation.
What is the September 2026 shelf prospectus?
The US$150 million base shelf was finalized September 15, 2026; the amended Form F-10 became effective September 16 under Rule 467(a). Effectiveness creates registration capacity, not cash. The September 16 supplement registers resale of 15,037,500 shares: 10,025,000 already issued and 5,012,500 issuable on warrant exercise. Resale proceeds belong to selling shareholders, not Cardiol; warrant exercise proceeds are a separate transaction. September 16 supplement; F-10 amendment.
Primary sources
- August 12, 2026 Form 6-K
- Q2 2026 condensed interim financial statements
- Q2 2026 Management’s Discussion and Analysis
- Q1 2026 statements used for the derived Q2 cash-use calculation
- July 2026 corporate presentation
- MAVERIC Phase III — ClinicalTrials.gov
- MAvERIC-Pilot Phase II — ClinicalTrials.gov
- MAvERIC-Pilot peer-reviewed JAHA article
- ARCHER Phase II — ClinicalTrials.gov
- ARCHER peer-reviewed ESC Heart Failure article
- Cardiol company pipeline
- Cardiol press release on MAVERIC enrollment
- Cardiol — Form 6-K Exhibit 99.1, September 23, 2026
- September 23, 2026 — MAVERIC reaches its original enrollment target; expansion planned
- September 20, 2026 — $150M Preliminary Shelf and Expanded Program Disclosure
- September 9, 2026 — H.C. Wainwright fireside chat on September 14
- August 12, 2026 — The loss narrowed to C$6.08M, the smallest quarter in two years
- September 23, 2026 — Cardiol — Form 6-K Exhibit 99.1, September 23, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CRDL or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
Risk disclosure. This Stock Hub is independent educational and informational content. It is not investment research, personalized financial advice, a recommendation, an offer or a solicitation to buy, sell or hold securities. CRDL is a speculative, pre-revenue biotech exposed to clinical, regulatory, manufacturing, financing, dilution, liquidity and binary-event risk, including partial or total loss of capital. Company statements about timelines, market opportunities, regulatory paths, cash runway and future results are forward looking and may prove wrong.
